U.S. pharma giant Johnson & Johnson (NYSE:JNJ) will report its second-quarter 2024 earnings on Wednesday, July 17. As per data from Benzinga Pro, analysts estimate sales of $22.29 billion and adjusted EPS of $2.71. Based on a quarterly review of events, management’s insights on product and market dynamics, and an analysis of prescription trends, a Goldman Sachs analyst says Johnson & Johnson is on track to meet its fiscal year 2024 guidance. For the second quarter, the analyst considers both their and the market’s revenue and EPS expectations reasonable. Related: Johnson & Johnson’s Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients. Goldman Sachs forecasts second-quarter sales of $22.5 billion, +6/0% on an adjusted operational ...